# Astex Pharmaceuticals, Inc. clinical trials: 45 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 45 trials with Astex Pharmaceuticals, Inc. as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Astex Pharmaceuticals, Inc.: 45 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/astex-pharmaceuticals-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 45
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 45, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| April 28, 2023 | NCT05835011 | A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic... | Astex Pharmaceuticals, Inc. | Phase 2 | Terminated | Myelodysplastic Syndromes | 2 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05835011) |
| July 8, 2021 | NCT04953923 | Thorough QT Assessment of Cedazuridine in Healthy Subjects | Astex Pharmaceuticals, Inc. | Phase 1 | Completed | Healthy Volunteers | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04953923) |
| November 19, 2020 | NCT04637009 | A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms | Astex Pharmaceuticals, Inc. | Phase 1 | Terminated | Acute Myeloid Leukemia, Myeloproliferative Neoplasm, Myelodysplastic/Myeloproliferative Neoplasm | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04637009) |
| July 21, 2020 | NCT04479800 | Effect of Food on the Pharmacokinetics of ASTX660 in Healthy Volunteers | Astex Pharmaceuticals, Inc. | Phase 1 | Completed | Healthy Volunteer | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04479800) |
| July 10, 2020 | NCT04466514 | A Phase 1 Study to Evaluate the Effect of Food on Pharmacokinetics of ASTX029 | Astex Pharmaceuticals, Inc. | Phase 1 | Completed | Healthy Volunteers | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04466514) |
| June 1, 2020 | NCT04411030 | A Study to Investigate the Effect of CYP3A4 Inhibition on the Single Dose Pharmacokinetics of ASTX660 and the Effect of a Single Dose of... | Astex Pharmaceuticals, Inc. | Phase 1 | Completed | Healthy Volunteer | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04411030) |
| November 7, 2019 | NCT04155580 | A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) | Astex Pharmaceuticals, Inc. | Phase 1 | Terminated | Acute Myeloid Leukemia | 68 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04155580) |
| January 23, 2019 | NCT03813186 | Effect of Food on Blood Levels of ASTX727 | Astex Pharmaceuticals, Inc. | Phase 1 | Completed | Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03813186) |
| July 27, 2018 | NCT03603964 | Guadecitabine Extension Study | Astex Pharmaceuticals, Inc. | Phase 2 | Terminated | Acute Myeloid Leukemia, Myeloid Dysplastic Syndrome | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03603964) |
| October 11, 2017 | NCT03306264 | Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML | Astex Pharmaceuticals, Inc. | Phase 3 | Completed | Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia | 227 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03306264) |
| September 30, 2016 | NCT02920008 | Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia | Astex Pharmaceuticals, Inc. | Phase 3 | Completed | Acute Myeloid Leukemia | 302 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02920008) |
| September 20, 2016 | NCT02907359 | Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs | Astex Pharmaceuticals, Inc. | Phase 3 | Completed | Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic | 417 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02907359) |
| January 28, 2015 | NCT02348489 | SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction | Astex Pharmaceuticals, Inc. | Phase 3 | Completed | Leukemia, Myeloid, Acute | 815 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02348489) |
| April 4, 2014 | NCT02103478 | Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients... | Astex Pharmaceuticals, Inc. | Phase 1/2 | Completed | Myelodysplastic Syndrome, MDS | 130 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02103478) |
| December 19, 2012 | NCT01752933 | SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) | Astex Pharmaceuticals, Inc. | Phase 2 | Completed | Hepatocellular Carcinoma | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01752933) |
| October 23, 2012 | NCT01712217 | A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib | Astex Pharmaceuticals, Inc. | Phase 1/2 | Completed | Non-small Cell Lung Cancer(NSCLC) | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01712217) |
| September 28, 2012 | NCT01696032 | SGI-110 in Combination With Carboplatin in Ovarian Cancer | Astex Pharmaceuticals, Inc. | Phase 2 | Completed | Ovarian Cancer | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01696032) |
| September 14, 2012 | NCT01685268 | A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate | Astex Pharmaceuticals, Inc. | Phase 1/2 | Completed | Prostate Cancer | 49 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01685268) |
| May 20, 2011 | NCT01357395 | A Phase 2, Open-Label Study of Amuvatinib in Combination With Platinum-Etoposide Chemotherapy in Small Cell Lung Cancer | Astex Pharmaceuticals, Inc. | Phase 2 | Completed | Small Cell Lung Carcinoma | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01357395) |
| February 11, 2011 | NCT01294202 | A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST | Astex Pharmaceuticals, Inc. | Phase 2 | Completed | Gastrointestinal Stromal Tumor (GIST) | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01294202) |
| December 16, 2010 | NCT01261312 | SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) | Astex Pharmaceuticals, Inc. | Phase 1/2 | Completed | MDS, CMML, AML | 414 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01261312) |
| November 11, 2010 | NCT01239108 | Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Relapsed/Refractory Leukemias | Astex Pharmaceuticals, Inc. | Phase 1 | Withdrawn | Relapsed/Refractory Leukemias | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01239108) |
| August 18, 2010 | NCT01183949 | Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma | Astex Pharmaceuticals, Inc. | Phase 1/2 | Completed | Multiple Myeloma | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01183949) |
| May 7, 2009 | NCT00894894 | Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of Oral MP470, a Multitargeted Tyrosine Kinase... | Astex Pharmaceuticals, Inc. | Phase 1 | Completed | Solid Tumors | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00894894) |
| April 15, 2009 | NCT00881166 | Safety of MP470 in Combination With Standard-of-Care Chemotherapy Regimens to Treat Solid Tumors | Astex Pharmaceuticals, Inc. | Phase 1 | Completed | Malignant Disease | 101 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00881166) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 13 |
| Phase 1/2 | 7 |
| Phase 2 | 15 |
| Phase 2/3 | 1 |
| Phase 3 | 8 |
| Not applicable | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 30 |
| Terminated | 9 |
| Unknown | 5 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Leukemia, Myeloid, Acute | 8 |
| Myelodysplastic Syndromes | 8 |
| Leukemia, Myelomonocytic, Chronic | 6 |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 4 |
| Pancreatic Neoplasms | 4 |
| Neoplasms | 3 |
| Primary Myelofibrosis | 2 |
| Prostatic Neoplasms | 2 |
| Lymphoma, Non-Hodgkin | 2 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 |
| Gastrointestinal Stromal Tumors | 2 |
| Carcinoma, Non-Small-Cell Lung | 2 |
| Blast Crisis | 1 |
| Breast Neoplasms | 1 |
| Myeloproliferative Disorders | 1 |
| Myelodysplastic-Myeloproliferative Diseases | 1 |
| Leukemia, Neutrophilic, Chronic | 1 |
| Polycythemia Vera | 1 |
| Thrombocythemia, Essential | 1 |
| Pdgfra-Associated Chronic Eosinophilic Leukemia | 1 |
| Pyloric Stenosis, Hypertrophic | 1 |
| Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | 1 |
| Thrombocytosis | 1 |
| Multiple Myeloma | 1 |
| Neoplasms, Plasma Cell | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Surgical supply companies in the United States](https://specstream.ai/data/businesses/surgical-supply-companies/united-states)
- [Bangladeshi restaurants in the United States](https://specstream.ai/data/businesses/bangladeshi-restaurants/united-states)
- [Environmental services in the United States](https://specstream.ai/data/businesses/environmental-services/united-states)
- [Machinery and tool manufacturers in the United States](https://specstream.ai/data/businesses/machinery-and-tool-manufacturers/united-states)
- [Scale suppliers in the United States](https://specstream.ai/data/businesses/scale-suppliers/united-states)
